ArticleHeliyon2018
Branched chain amino acids attenuate major pathologies in mouse models of retinal degeneration and glaucoma.
Article in Heliyon, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 51 citations in OpenAlex.
- Post hoc analysis of a randomized placebo-controlled trial suggests potential visual benefits of branched-chain amino acids in retinitis pigmentosa.Scientific reports · 2025Trial
- Efficacy and Safety of Branched Chain Amino Acids on Retinitis Pigmentosa: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Translational vision science & technology · 2024Trial
- Increased Gut Microbiota Diversity in Patients With Retinitis Pigmentosa and Implications for Disease Phenotypes and Progression.Investigative ophthalmology & visual science · 2026Article
- Author Response: The Future of Retinitis Pigmentosa Research: Unlocking the Potential of Branched-Chain Amino Acid Therapy.Translational vision science & technology · 2025Article
- Accumulation of branched-chain amino acids deteriorates the neuroinflammatory response of Müller cells in diabetic retinopathy via leucine/Sestrin2-mediated sensing of mTOR signaling.Acta diabetologica · 2025Article
- Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study.Investigative ophthalmology & visual science · 2024Article
- Distinct and Overlapping Metabolites Associated with Visual Impairment and Cognitive Impairment.Journal of Alzheimer's disease reports · 2024Article
- Pyrroloquinoline quinone drives ATP synthesis in vitro and in vivo and provides retinal ganglion cell neuroprotection.Acta neuropathologica communications · 2023Article
- Branched-Chain Amino Acids Metabolism and Their Roles in Retinopathy: From Relevance to Mechanism.Nutrients · 2023Review
- Branched Chain Amino Acids Promote ATP Production Via Translocation of Glucose Transporters.Investigative ophthalmology & visual science · 2022Article
- One-step induction of photoreceptor-like cells from human iPSCs by delivering transcription factors.iScience · 2022Article
- Hop flower extracts mitigate retinal ganglion cell degeneration in a glaucoma mouse model.Scientific reports · 2020Article
- Suppression of cGMP-Dependent Photoreceptor Cytotoxicity With Mycophenolate Is Neuroprotective in Murine Models of Retinitis Pigmentosa.Investigative ophthalmology & visual science · 2020Article
- Adenosine triphosphate maintenance by branched chain amino acids as a novel neuroprotective strategy for retinal neurodegenerative diseases.Neural regeneration research · 2019Article
- Plasma Metabolites Associated with OCT Features of Age-Related Macular Degeneration.Ophthalmology scienceArticle
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal neuronal cell death underlies many incurable eye diseases such as retinitis pigmentosa (RP) and glaucoma, and causes adult blindness. We have shown that maintenance of ATP levels via inhibiting ATP consumption is a promising strategy for preventing neuronal cell death. Here, we show that branched chain amino acids (BCAAs) are able to increase ATP production by enhancing glycolysis. In cell culture, supplementation of the culture media with BCAAs, but not glucose alone, enhanced cellular ATP levels, which was canceled by a glycolysis inhibitor. Administration of BCAAs to RP mouse models,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.